It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by Royal Bank of Canada from ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, ...

Regeneron (REGN) came out with quarterly earnings of $12.46 per share, beating the Zacks Consensus Estimate of $11.75 per share. This compares to earnings of $11.59 per share a year ago. These figures ...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter ...